On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs ...

The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

The approval was based on results from the TROPION-Breast01 Phase III trial.

Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the ...

AstraZeneca announced on Monday that it has secured approval from the US Food and Drug Administration, alongside Daiichi ...